IL313897A - Methods for reducing atopic dermatitis by administering an IL-4/IL-13 antagonist - Google Patents

Methods for reducing atopic dermatitis by administering an IL-4/IL-13 antagonist

Info

Publication number
IL313897A
IL313897A IL313897A IL31389724A IL313897A IL 313897 A IL313897 A IL 313897A IL 313897 A IL313897 A IL 313897A IL 31389724 A IL31389724 A IL 31389724A IL 313897 A IL313897 A IL 313897A
Authority
IL
Israel
Prior art keywords
attenuating
antagonist
administering
methods
atopic march
Prior art date
Application number
IL313897A
Other languages
English (en)
Hebrew (he)
Inventor
Gregory Geba
Dateng Li
Judy Xiang Li
Original Assignee
Regeneron Pharma
Gregory Geba
Dateng Li
Judy Xiang Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Gregory Geba, Dateng Li, Judy Xiang Li filed Critical Regeneron Pharma
Publication of IL313897A publication Critical patent/IL313897A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL313897A 2021-12-30 2022-12-29 Methods for reducing atopic dermatitis by administering an IL-4/IL-13 antagonist IL313897A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163295113P 2021-12-30 2021-12-30
PCT/US2022/082535 WO2023130010A1 (en) 2021-12-30 2022-12-29 Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Publications (1)

Publication Number Publication Date
IL313897A true IL313897A (en) 2024-08-01

Family

ID=85199428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313897A IL313897A (en) 2021-12-30 2022-12-29 Methods for reducing atopic dermatitis by administering an IL-4/IL-13 antagonist

Country Status (10)

Country Link
US (1) US20230220089A1 (https=)
EP (1) EP4457245A1 (https=)
JP (1) JP2025501239A (https=)
KR (1) KR20240135618A (https=)
CN (1) CN118355034A (https=)
AU (1) AU2022425608A1 (https=)
CA (1) CA3241374A1 (https=)
IL (1) IL313897A (https=)
MX (1) MX2024006053A (https=)
WO (1) WO2023130010A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
CA2646626A1 (en) 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
JP2010502224A (ja) 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012049278A1 (en) 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
PT3889181T (pt) * 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
JP2016522168A (ja) 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN111686247B (zh) 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
CN111592597B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
MX2022011730A (es) * 2020-03-27 2022-10-13 Regeneron Pharma Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
US20230374144A1 (en) 2020-09-10 2023-11-23 Staidson (Beijing) Biopharmaceutical Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof
KR20230123981A (ko) 2020-12-23 2023-08-24 누맙 세러퓨틱스 아게 Il-4r에 결합하는 항체 가변 도메인
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31

Also Published As

Publication number Publication date
CA3241374A1 (en) 2023-07-06
EP4457245A1 (en) 2024-11-06
WO2023130010A1 (en) 2023-07-06
US20230220089A1 (en) 2023-07-13
JP2025501239A (ja) 2025-01-17
CN118355034A (zh) 2024-07-16
AU2022425608A1 (en) 2024-08-15
WO2023130010A8 (en) 2023-08-10
MX2024006053A (es) 2024-07-29
KR20240135618A (ko) 2024-09-11

Similar Documents

Publication Publication Date Title
IL289930A (en) Methods for treating atopic dermatitis using an IL-4R antagonist
IL313897A (en) Methods for reducing atopic dermatitis by administering an IL-4/IL-13 antagonist
SG11202009371WA (en) Methods for treating atopic dermatitis by administering an il-4r inhibitor
IL320913A (en) Spirocyclic dihydropyranopyrimidine KRAS inhibitors
IL287902A (en) Methods of administering certain vmat2 inhibitors
NZ790629A (en) Uses of il-13 antagonists for treating atopic dermatitis
IL287275A (en) Methods of treating or preventing asthma by administering an IL-33 agonist
IL326518A (en) Spirocyclic dihydropyranopyrimidine KRAS inhibitors
SG11201510506RA (en) Apparatus and method for improved concealment of the adaptive codebook in acelp-like concealment employing improved pulse resynchronization
PT3920912T (pt) Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL310962A (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
IL289731A (en) Methods for treating or preventing asthma by administering an antagonist to il-4r
IL277255A (en) Preparations and methods for assessing the attenuation and infectivity of Listeria strains
EP3784785A4 (en) DOWNREGULATION OF SNCA EXPRESSION BY TARGETED EDITING OF DNA METHYLATION
GB201913383D0 (en) Methods for predicting patient response to DMARDs
GB202019188D0 (en) Methods for adaptive radiotherapy
HK40111305A (en) Methods for attenuating atopic march by administering an il-4/il-13 antagonist
IL293544A (en) Methods for treating COPD by giving IL-33 antagonist
IL312187A (en) Methods for treating prurigo nodularis by administering an IL-4R antagonist
GB2586489B (en) Method and structures for coil adjustment
GB2577341B (en) Method of manufacturing an assembly for use as an isolation barrier
IL264463A (en) Device and method for disinfecting herbs using plasma
IL288288A (en) Method for providing safe administration of anti-cd40 antibody
EP3956420C0 (de) Verfahren zur herstellung von holzkohle
GB201910655D0 (en) Method for detection of bacteria